Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine

• Status: Recruiting
• Trial end date: 2021-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the use of sugammadex (compared with neostigmine) reduces the rate of postoperative pulmonary complications (PPCs).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northern Sydney Anaesthesia Research Institute
• Collaborators: Merck Sharp & Dohme Corp.; Northern Sydney and Central Coast Area Health Service
• Treatments: Glycopyrrolate; Neostigmine

Criteria

Inclusion Criteria:

• age >18

• patients presenting for non-cardiac surgery

• planned operative time of over 1 hour

• plan to be intubated and to receive muscle relaxants for their surgery

• plan to stay at least one night in hospital

Exclusion Criteria:

• Previous recruitment to the trial

• Hypersensitivity to any of the study drugs

• Patient refusal

• Cognitive Impairment, or language proficiency leading to inability to complete QoR-15 questionnaire

• Body Mass Index (BMI) >40

• Planned postoperative intubation and ventilation

• Liver failure with Child-Pugh class B/C

• Renal failure with either regular peritoneal or haemodialysis or serum creatinine >140mcgmol/L

• Women lactating, pregnant or of childbearing potential who are not willing to avoid pregnancy during the study